Penny Prophet

I am not a financial advisor, I just play one on Twitter. Do not buy/sell based on my tweets.

[BriaCell Therapeutics Corp. @BriaCell]

BriaCell announced that the Data Safety Monitoring Board (DSMB), has recommended continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ + CPI combination regimen in #metastaticbreastcancer. Find details: https://t.co/HhuP8KqtHx $BCTX $BCTXW

[John Zidar aka/ Stock Wizard @JohnZidar]

$BCTX - BriaCell
🔹Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer

👆 7.9% PreM/ $1.06

[stock setter @MarcJacksonLA]

$BCTX $BCTXW
- BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer
https://t.co/l7QzL8UZI1

[Penny Prophet @PennyProphets]

$bctx as I’ve always said, know what you own. We have a winner here, folks.

[Penny Prophet @PennyProphets]

$BCTX leggggooooooo

[Synthetic.com @syntheticdotcom]

Director/insider Marc Lustig purchased $2 million $BCTX

[Life Science Report @lifesciencerpt]

BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024 $BCTX https://t.co/Cgttx3NTWE

[Penny Prophet @PennyProphets]

$BCTX adding

[Penny Prophet @PennyProphets]

$BCTX just reloaded for #LT

[BriaCell Therapeutics Corp. @BriaCell]

BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset. For more information: https://t.co/pT8h1AMgaT $BCTX $BCTXW

[BriaCell Therapeutics Corp. @BriaCell]

BriaCell reported remarkable improvement of eye-bulging “proptosis” and significant ocular pain reduction in a patient that failed 7 prior regimens, after only 3 cycles of Bria-IMT™+ CPI #Immunotherapy. Find details: https://t.co/C3BBxMwVtv $BCTX $BCTXW

[BriaCell Therapeutics Corp. @BriaCell]

The strong survival and clinical benefits observed in evaluable and ADC resistant patients support the use of the current formulation in BriaCell’s pivotal Phase 3 study in advanced #breastcancer. https://t.co/qLW9cMcVHw $BCTX $BCTXW

[Penny Prophet @PennyProphets]

$BCTX BCTXW - Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing

Know what you own! Loading more. #LT position will be a massive winner IMO.

[BriaCell Therapeutics Corp. @BriaCell]

32 out of 42 patients treated since 2022 remain alive suggesting consistently strong survival benefit. https://t.co/vhg6kpPako $BCTX $BCTXW

[BriaCell Therapeutics Corp. @BriaCell]

BriaCell reported a powerful anti-tumor response associated with reduction in proptosis (eye-bulging) and reduced ocular pain in a patient that failed 7 prior regimens, after only 3 cycles of the Bria-IMT™ combination regimen. Learn more: https://t.co/C3BBxMwVtv $BCTX $BCTXW

[BriaCell Therapeutics Corp. @BriaCell]

CEO, Dr. Williams, emphasizes the remarkable anti-tumor response and significant reduction in ocular pain reported in a heavily pre-treated advanced #breastcancer patient in the Phase 2 study of BriaCell’s Bria-IMT™ combination regimen. https://t.co/C3BBxMwVtv $BCTX $BCTXW

[BriaCell Therapeutics Corp. @BriaCell]

71% intracranial objective response rate (iORR) in BriaCell patients with central nervous system (CNS) metastases support clinical efficacy of Bria-IMT™, alone and in combination with an immune checkpoint inhibitor (CPI). https://t.co/WXXR4hFDSh $BCTX $BCTXW

[BioDonor™ @BioDonor]

$BCTX $5.64 BriaCell Therapeutics price target $18 reiterated by HC Wainwright with a buy rating.

[BriaCell Therapeutics Corp. @BriaCell]

The tumor reductions observed in heavily pretreated patients highlight the potential clinical benefit of Bria-IMT™ in managing CNS metastases. https://t.co/WXXR4hFDSh $BCTX $BCTXW

[Penny Prophet @PennyProphets]

$BCTX doing its thing. Know what you own! IMO we have a #LT winner here.